A preliminary study on reduced dose (33 or 25 μg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization–embryo transfer

References

• Brinsden P R. A textbook of in vitro fertilization and assisted reproduction. 2nd ed. Parthenon Publishing Group Inc., New York 1999; 83–89
   Google Scholar
• Fenichel P, Grimaldi M, Olivero J F. Predictive value of hormonal profiles before stimulation of IVF. Fertil Steril 1989; 51: 845–849
   PubMed Web of Science ®Google Scholar
• Scott R T, Toner J F, Mausher S J. FSH levels on cycle day 3 are predictive of IVF outcome. Fertil Steril 1989; 51: 651–654
   PubMed Web of Science ®Google Scholar
• Toner J P, Philput C B, Mausher S J. Basal FSH level is a better predictor of IVF performance than age. Fertil Steril 1991; 55: 784–791
   PubMed Web of Science ®Google Scholar
• Karande V, Jones G, Veeck L, Muasher S J. High-dose FSH stimulation at the onset of the menstrual cycle does not improve IVF outcome of low-responder patients. Fertil Steril 1990; 53: 486–490
   PubMed Web of Science ®Google Scholar
• Janssens R MJ, Vermeiden J PW, Lambalk C B, Schats R, Schoemaker J. Gonadotropin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF. Hum Reprod 1998; 13: 2386–2391
   PubMedGoogle Scholar
• Janssens R MJ, Lambalk C B, Vermeiden J PW, Schats R, Bernards J M, Rekers-Mombarg L T, Schoemaker J. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000; 15: 2333–2340
   PubMed Web of Science ®Google Scholar
• Sandow J, Donnez J. Clinical pharmacokinetics of LHRH analogues. LHRH analogues in gynaecology, I Brosens, H S Jacob, B Runnenbaum. Parthenon Publishing, Lancashire 1990; 17–31
   Google Scholar
• Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2001; 76: 532–537
   PubMedGoogle Scholar
• Leondires M P, Escalpes M, Segars J H, Scott R T, Jr, Miller B T. Microdose follicular phase gonadotropin-releasing hormone agonists(GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. Fertil Steril 1999; 72: 1018–1023
   PubMed Web of Science ®Google Scholar
• Kim S H, Ku S Y, Jee B C, Suh C S, Moon S Y, Lee J Y. Clinical significance of transvaginal color Doppler ultrasonography of the ovarian artery as a predictor of ovarian response in controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer. J Assist Reprod Genet 2002; 19: 103–112
   PubMedGoogle Scholar
• Ku S Y, Suh C S, Kim S H, Choi Y M, Kim J G, Moon S Y. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction. Eur J Obstet Gynecol Reprod Biol 2003; 109: 55–59
   PubMed Web of Science ®Google Scholar
• Monroe S E, Blumenfeld Z, Andreyko J L, Schriock E, Henzl M R, Jaffe R B. Dose-dependent inhibition of pituitary–ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin). J Clin Endocrinol Metab 1986; 63: 1334–1341
   PubMed Web of Science ®Google Scholar
• Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas A T, Comaru-Schally A M, Schally A V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982; 79: 1658–1662
   PubMed Web of Science ®Google Scholar
• Ben-Rafael Z, Lipitz S, Bider D, Mashiach S. Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone-agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 1991; 55: 272–275
   PubMedGoogle Scholar
• Broekmans F J, Hompes P GA, Lambalk C B, Schoute E, Broeders A, Schoemaker J. Short term pituitary desensitization: effects of different doses of the gonadotrophin-releasing hormone agonist triptorelin. Hum Reprod 1996; 11: 55–60
   PubMed Web of Science ®Google Scholar
• Simon A, Benshushan A, Shushan A, Zajicek G, Dorembus D, Lewin A, Laufer N. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization. Hum Reprod 1994; 9: 1813–1817
   PubMedGoogle Scholar
• Elgendy M, Afnan M, Holder R, Lashen H, Afifi Y, Lenton W, Sharif K. Reducing the dose of gonadotrophin hormone agonist on starting ovarian stimulation: effect in ovarian response and in-vitro fertilization outcome. Hum Reprod 1998; 13: 2382–2385
   PubMedGoogle Scholar
• Dal Prato L, Borini A, Trevisi M R, Bonu M A, Sereni E, Flamigni C. Effect of reduced dose of triptorelin at the start of ovarian stimulation on the outcome of IVF: a randomized study. Hum Reprod 2001; 16: 1409–1414
   PubMedGoogle Scholar
• Navot D, Rosenwaks Z, Anderson F, Hodgen G D. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys. Fertil Steril 1991; 55: 1069–1075
   PubMedGoogle Scholar
• Feldberg D, Farhi J, Ashkenazi J. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone level. Fertil Steril 1994; 62: 343–346
   PubMed Web of Science ®Google Scholar
• Olivennes F, Righini C, Fanchin R, Torrisi C, Hazout A, Glissant M, Fernandez H, Frydman F. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle stimulating hormone concentrations on day 3. Hum Reprod 1996; 11: 1169–1172
   PubMed Web of Science ®Google Scholar